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Abstract
Background: We present a lipidomics analysis of human Parkinson’s disease tissues. We have focused on the primary visual
cortex, a region that is devoid of pathological changes and Lewy bodies; and two additional regions, the amygdala and
anterior cingulate cortex which contain Lewy bodies at different disease stages but do not have as severe degeneration as
the substantia nigra.
Methodology/Principal Findings: Using liquid chromatography mass spectrometry lipidomics techniques for an initial
screen of 200 lipid species, significant changes in 79 sphingolipid, glycerophospholipid and cholesterol species were
detected in the visual cortex of Parkinson’s disease patients (n=10) compared to controls (n=10) as assessed by two-sided
unpaired t-test (p-value ,0.05). False discovery rate analysis confirmed that 73 of these 79 lipid species were significantly
changed in the visual cortex (q-value ,0.05). By contrast, changes in 17 and 12 lipid species were identified in the
Parkinson’s disease amygdala and anterior cingulate cortex, respectively, compared to controls; none of which remained
significant after false discovery rate analysis. Using gas chromatography mass spectrometry techniques, 6 out of 7 oxysterols
analysed from both non-enzymatic and enzymatic pathways were also selectively increased in the Parkinson’s disease visual
cortex. Many of these changes in visual cortex lipids were correlated with relevant changes in the expression of genes
involved in lipid metabolism and an oxidative stress response as determined by quantitative polymerase chain reaction
techniques.
Conclusions/Significance: The data indicate that changes in lipid metabolism occur in the Parkinson’s disease visual cortex
in the absence of obvious pathology. This suggests that normalization of lipid metabolism and/or oxidative stress status in
the visual cortex may represent a novel route for treatment of non-motor symptoms, such as visual hallucinations, that are
experienced by a majority of Parkinson’s disease patients.
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Introduction
Parkinson’s disease (PD) is an idiopathic neurodegenerative
movement disorder with a prevalence of approximately 1–2% of
the population over 65 years increasing to 3–5% in people over 85
years old [1,2]. Pathologically, PD classically presents with specific
loss of dopaminergic neurons in the substantia nigra pars
compacta (SN) and Lewy body formation [3]. Lewy bodies are
composed of aggregated proteins including alpha-synuclein (a-syn)
and other components including lipids [4,5]. According to the
Braak PD staging scheme, selective structures of the brainstem,
temporal mesocortex and neocortex become progressively in-
volved over time, with severe destruction of the SN and
involvement of the amygdala (AMY) by stage 4, and the anterior
cingulate cortex (ACC) affected by stage 5 [6,7]. The occipital
cortex is pathologically spared in PD [3,6,8]. The attractiveness of
the Braak staging scheme is that it explains many of non-motor
symptoms in PD [8], although there is controversy over this
concept [9,10].
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sleep disturbances, autonomic dysfunction, sensory complica-
tions, olfactory deficits, and neuropsychiatric problems. Of these
neuropsychiatric symptoms, visual hallucinations (VH) are one of
the most common. In a recent 20 year follow-up study, VH were
present at a prevalence of 74% in idiopathic PD patients [11].
Other studies of shorter follow-up duration have indicated VH
prevalence in the range of ,50 to 75% [12–15]. Although VH
were initially suggested to be a complication of treatment, it is
now thought that changes in neural circuits underlie the
dysfunction of visual pathways [16]. Structural MRI studies have
shown that PD patients with VH present with grey matter
atrophy of the occipito-parietal and hippocampal regions of the
brain [17–19]. In addition to this, PET and functional MRI
studies have demonstrated reduced activation of the ventral/
lateral visual association cortices and the primary visual cortex
(VC) in particular [20–23]. To date, there is no evidence of
pathology in the VC of PD patients [7], even though dysfunction
of this region is associated with VH. This implies that metabolic
changes in the VC could contribute to the dysfunction of visual
perception in PD.
Maintenance of lipid homeostasis is increasingly recognized as a
crucial factor for normal neuronal function. There are several
reasons to suspect that modulation of cerebral lipid metabolism or
transport may be linked to PD. These include the findings that a-
syn is a lipid binding protein and that it deposits with lipids
associated with Lewy bodies and neuromelanin in PD tissues
[4,5,24]. Genetic deletion of a-syn in mice results in increased
levels of cerebral cholesterol, cholesteryl esters and triacylglycerols
[25], whereas changes in multiple classes of phospholipids were
detected in old (but not young) transgenic mice expressing human
a-syn [26]. Recent studies also suggest that the association of a-syn
with oxidized lipid metabolites can lead to mitochondrial
dysfunction in PD [27]. Other studies have suggested changes in
cerebral cholesterol, oxysterols, and cholesterol hydroperoxides
may be related to PD progression [28–30] and it has been
established that mutations in the GBA gene, that encodes
glucocerebrosidase, confer increased risk for PD [31,32]. Taken
together, these studies suggest that changes in cerebral lipid
homeostasis may contribute to neurodegenerative pathways in PD
and possibly also to deficits in the VC that currently have no
known pathological basis.
Lipidomics is as a powerful research tool that can be utilised to
investigate lipid pathways that play important roles in cell biology
and in specific disease processes. Lipidomics approaches have
therefore been used to investigate lipid metabolism at the cellular
level, in animal studies and increasingly in the human pathophys-
iological context [33–42]. In the present study we have undertaken
the first lipidomics analysis of human PD tissues. We have focused
on the primary VC and two additional brain regions, the AMY
and ACC which contain Lewy bodies at different disease stages
but do not have as severe degeneration as the SN at end-stage PD.
The lipidomics data was confirmed by follow-up mass spectrom-
etry and high-performance liquid chromatography (HPLC)
techniques that were used to inform a targeted assessment of lipid
pathway gene expression. Our data reveal substantial changes in
sphingolipid and glycerophospholipid biosynthetic pathways in the
VC of PD patients compared to controls. Levels of oxysterols
derived from both non-enzymatic (free radical-mediated) and
enzymatic pathways were also increased in the PD VC. Many of
these changes in VC lipids were correlated with relevant changes
in the expression of genes involved in lipid metabolism and an
oxidative stress response.














Con 1 93 F - N 21 0 0
Con 2 83 F - N 7 0 0
Con 3 79 M - N 8 0 0
Con 4 102 F - N 5 0 0
Con 5 92 F - N 16 0 0
Con 6 86 M - N 15 0 I
Con 7 85 M - N 9 0 I
Con 8 88 M - N 9 0 II
Con 9 87 F - N 5 0 0
Con 10 85 F - N 10 0 II
PD 1 78 M 24 Y 6 V 0
PD 2 84 M 17 N 7 IV 0
PD 3 66 M 12 Y 6 V 0
PD 4 91 F 10 Y 4 IV III
PD 5 83 F 14 Y 32 V III
PD 6 90 M 15 N 5 V 0
PD 7 72 M 9 N 4 IV 0
PD 8 83 F 14 Y 7 V 0
PD 9 75 M 14 Y 9 V II
PD 10 69 M 17 Y 5 V I
doi:10.1371/journal.pone.0017299.t001
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Ethics statement
This research was conducted according to the principles
expressed in the Declaration of Helsinki. Ethics approval was
from the University of New South Wales Human Research Ethics
Committee.
Materials
All organic solvents used were of analytical/HPLC grade and
purchased from Merck (Darmsdadt, Germany). Standard solutions
of oxysterols, 5-alpha cholestane, and other cholesterol biosyn-
thetic precursors were diluted in ethanol. Formic acid, acetic acid
(Lancaster, England), potassium hydroxide, butylated hydroxyto-
luene (BHT), ethanol, acetic acid (Merck, Darmstadt, Germany),
and hexane (Tedia, OH, USA) were of analytical grade. Methanol
(EM Science, Darmstadt, Germany) and ethyl acetate (Fisher
Scientific, UK) were of HPLC grade. Oasis mixed anion-exchange
cartridges were from Waters Corp. (Milford, MA, USA).
Recombinant human a-syn protein used as a Western blot
standard was generously provided by Wei Ping Gai, Flinders
University, Adelaide, Australia.
Human Brain Tissue
Frozen grey matter brain tissue from 10 sporadic PD cases and
10 control cases was received from the Sydney Brain Bank and the
NSW Tissue Resource Centre, part of the Australian Brain Bank
Network funded by the National Health and Medical Research
Council of Australia. Standardized clinicopathological criteria
were used for diagnosis [43]. The demographic and basic clinical
and neuropathological details for all cases and controls are
provided in Table 1.
The PD cases had a mean age of 7969 y, a mean disease
duration of 1564 y and a mean postmortem interval of 8.568h .
The controls were 9 years older on average (mean age of 8866y ,
t-test p=0.02) and had a similar postmortem interval (mean of
10.565h ,t-test p=0.5). Age was factored into the analyses as
described in the Results section. There was no difference in the sex
distribution between groups (x
2 p=0.37) and both groups had
similar causes of death; which included pneumonia (2 PD, 2
controls), terminal prostate cancer (1 PD, 1 control), sepsis/renal
failure (1 PD, 1 control) and cardiac events or cardiorespiratory
arrest (remaining PD and controls).
Approximately 500 mg of frozen brain tissue from the AMY,
ACC and VC was pulverized over dry ice and four aliquots of
approximately 10 mg, 50 mg, 100 mg, 100 mg of accurately
weighed pulverised tissue samples were frozen and stored at
280uC until required for analysis by Western blotting, mass
spectrometry, HPLC or quantitative real-time (qRT-PCR). These
methods are briefly summarised below and a full description is
included as Methods S1. A schematic diagram outlining the
workflow of the complete lipidomic screening strategy is also
included as Figure S1.
Western blotting for a-syn and synaptophysin
The brain tissue was homogenized into three fractions as
described previously [44,45] to provide homogenates that were
soluble in tris-buffered saline (TBS), TBS containing 1% (w/v)
Triton X-100 (TX) and an SDS-solublized pellet fraction (SDS).
Equal amounts of protein were then analysed by SDS-PAGE and
Western blotting using a-syn or synaptophysin monoclonal
antibodies and re-probed with a rabbit b-actin polyclonal
antibody. Signal intensities were quantified using NIH Image J
software (National Institutes of Health, Bethesda, MD) with the
relative expression of bands of interest normalised to b-actin. Full
details are included as Methods S1.
Analysis of lipids using high performance liquid
chromatography/mass spectrometry (LC/MS) and gas
chromatography/mass spectrometry (GC/MS)
Lipids were extracted from tissue samples containing internal
standards and heavy isotopes using a modified Bligh and Dyer
extraction method [46]. The lipid extract was split into two
aliquots for LC/MS and GC/MS. For the LC/MS analysis an
Agilent high performance liquid chromatography (HPLC) 1200
system coupled with an Applied Biosystem Triple Quadrupole/
Ion Trap mass spectrometer (3200 Qtrap) was used for
quantification of individual phospholipids and sphingolipids
[42,47]. Neutral lipids were analyzed using a modified method
from a previously described LC/MS method [48]. Free cholesterol
was quantified using a HPLC atmospheric pressure chemical
ionisation MS (LC/APCI/MS) method [49]. For the GC/MS
analysis, aliquots of lipid extracts prepared as for LC/MS above
were analysed using an Agilent 5975 inert XL mass selective
detector and 5973 gas chromatograph equipped with an automatic
Figure 1. Analysis of a-synuclein and synaptophysin in
fractionated Parkinson’s disease tissues. Tissues were homoge-
nised into three fractions that contained tris-buffered saline (TBS), TBS
containing Triton X100 (TX) or sodium dodecyl sulphate (SDS) and a-
synuclein (a-Syn), synaptophysin (Sp) and b-actin expression was
analysed by Western blotting (A). The intensity of the bands was
measured and the relative amounts of a-Syn and Sp in each fraction is
expressed in the histogram (B). The data are derived from Parkinson’s
disease amygdala (PD AMY) samples and are used as an example to
illustrate the techniques used to characterise the PD tissues. Data in ‘‘B’’
represent mean values with SEM shown by the error bars for the three
samples shown in ‘‘A’’.
doi:10.1371/journal.pone.0017299.g001
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Methods S1.
Electrospray ionisation MS
Samples were also analysed by direct ESI/MS. In brief, lipids
were extracted using published methods [50,51] and mass spectra
were obtained using a Waters QuattroMicro
TM (Waters, Man-
chester, U.K.) equipped with a z-spray electrospray ion source.
Samples were infused into the electrospray ion source and
sphingolipids and ceramides analysed as described previously
[50,52,53]. Full details are included as Methods S1.
High performance liquid chromatography
Cholesterol and a-tocopherol content of brain tissue was
determined by reversed-phase HPLC using a C18 reversed phase
column as described previously [54]. Trace amounts of [3H]-
cholesterol were used as an internal standard. Full details are
included as Methods S1.
Quantitative real-time PCR
The qRT-PCR analysis of human brain samples was performed
using our established methods [55]. Brain tissue was homogenized
in TRIzol reagent (Invitrogen, Mount Waverly, Australia) and
RNA concentration was determined spectrophometrically with a
Nanodrop 1000 (Thermo scientific, Wilmington, DE). Five mgo f
total RNA was used for reverse transcription with random primers
and M-MLV reverse transcriptase (Promega, Sydney, Australia).
The resulting cDNA provided the template in the qRT-PCR,
which was carried out using a Mastercycler EP Realplex S
(Eppendorf, North Ryde, Australia). qRT-PCR of the house
keeping gene, b-actin was also performed for each cDNA template
and gene expression normalised to b-actin. RNA integrity was
confirmed using a high resolution Bioanalyzer electrophoresis
system (Agilent Technologies, Palo Alto, CA, USA) as described
previously [55]. Full details are included as Methods S1. All
primers were purchased from Sigma (Castle Hill, Australia) and
details of the sequences are provided as Table S1.
Statistics
Data presented are expressed as mean with SEM shown by the
error bars. Statistical significance was analysed using the two-sided
unpaired t-test and SPSS Statistics software (version 17, SPSS Inc.
Chicago, IL). A p-value ,0.05 was considered significant. For the
lipidomics datasets, false discovery rate (FDR) q-values were
calculated from the t-test p-values [56].
Results
Characterisation of a-syn and synaptophysin expression
The PD Braak staging for the cases and controls is given in
Table 1. In order to provide a biochemical correlate of Lewy body
pathology in the corresponding small tissue samples that we
analysed, Western blotting for a-syn in SDS-soluble fractions of
brain homogenate was performed [45]. As an example, AMY
samples derived from PD cases are shown in Figure 1. a-Syn was
detected predominantly in the TBS-soluble (41%) and TX-soluble
(54%) fractions with a small but reproducibly detectable portion
(5%) also detected in the SDS-soluble fraction (Fig. 1A,B). The
Figure 2. Analysis of control (Con) and Parkinson’s disease (PD) a-synuclein (a-Syn) and synaptophysin (Sp) levels. Tissues were
homogenised and fractionated as described in the legend to Figure 1 and insoluble a-Syn in the SDS fraction, and Sp in the TX-fraction was measured
in the anterior cingulate cortex (ACC) (A), amygdala (AMY) (B), and visual cortex (VC) (C). Corresponding quantification of relative a-Syn (D) and Sp (E)
protein expression in the three brain regions is provided in the histograms. Data represent mean 6 SEM (n=10), **p,0.001 by t-test.
doi:10.1371/journal.pone.0017299.g002
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deposition in Lewy bodies [3]. In approximately 50% of PD cases,
we also detected apparent high molecular weight (HMW) species
of a-syn in the SDS fraction of the AMY (Fig. S2). A 31 kDa a-syn
band was one of the clearest HMW bands detected; although a
previous study has suggested this may be due to non-specific
binding of the detection antibody [45]. These HMW species
accounted for only a minor proportion of total a-syn and because
they were not consistently observed, they were not quantified in
the present study. Synaptophysin was also measured in the
samples as a control for the fractionation method (as the
membrane-bound synaptophysin should appear predominantly
in the TX fraction) and as a surrogate marker for synaptic density/
neuron loss. As predicted, the vast majority (91%) of synaptophy-
sin was recovered in the TX fraction (Fig. 1A,B).
The amounts of a-syn in the SDS-soluble fractions were then
used to estimate relative Lewy body pathology in all samples. The
data indicate that a-syn deposition was significantly increased in
the SDS-soluble fractions of the AMY of the PD cases as
compared to the controls (Fig. 2). A non-significant trend for
increased a-syn deposition in the ACC was also noted whereas
there were no changes in the VC (Fig. 2). This is consistent with
the Braak stages for these cases with ACC Lewy bodies (Braak PD
stage V) found in 7/10 of the PD cases (Table 1). Synaptophysin
levels were not altered in any of the samples analysed, suggesting
that extensive neurodegeneration or synaptic loss was not a feature
of the brain regions analysed in this PD cohort (Fig. 2).
LC/MS lipidomics assessment of control and PD tissues
A lipidomics analysis of ACC, AMY and VC tissues from both
control and PD brains was then conducted. We initially focused on
200 lipid species that we categorised into three broad familes:
sphingolipids (including C18-sphingosine, C18-dihydrosphingosine
and multiple molecular species of sphingomyelin (SM), ceramide
(Cer), ganglioside GM3 (GM3) and sulfatide (SL); glyceropho-
spholipids (including multiple molecular species of phosphatidic acid
(PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE),
phosphatidylinositol (PI) and phosphatidylserine (PS); and neutral
lipids (including cholesterol and multiple molecular species of
cholesteryl esters (CE), triacylglycerides (TAG) and diacylglycer-
ides (DAG). In this analysis, each individual lipid in the PD
samples was quantified relative to the levels detected in Con
samples. The ‘‘heat map’’ of these lipid changes indicates
significant changes in all brain areas examined (Fig. 3). Clearly,
however, most of the statistically significant changes in lipid levels
were detected in the VC (Fig. 3, Tables S2–S4). One issue that
needs to be considered is the possibility that false discoveries are
made due to the large number of test variables assessed using a
lipidomics approach. We therefore used a robust method for
estimating false discovery rates (FDR) that calculates q-values
based on p-values derived from t-test analysis [56]. With a q-value
threshold set at 5%, 73 of the 79 significant differences identified
in the VC by the t-test remained statistically significant (Table S5).
In contrast, all 17 and all 12 of the differences observed in the
AMY and ACC were found to have q-values .0.05 (Table S5).
This suggests that the changes detected in the VC are not due to
chance whereas the changes detected in the AMY and ACC may
be false positives and need to be interpreted with caution.
In the PD VC, the lipidomics data indicated an overall increase
in sphingolipid levels, a decrease in PE accompanied by an
increase in PS, and an overall increase in cholesterol and DAG
(Fig. 3). To confirm the PD-related changes in lipid profiles
identified by the lipidomics approach, independent quantitative
lipid analysis methods were employed using the same Con (n=10)
and PD (n=10) samples. To assess the possible influence of the
10% older age of the Con subjects (see Materials and Methods
section), additional analyses were also performed that excluded the
two oldest Con subjects and the two youngest PD subjects to
provide age-matched groups (i.e. Con (n=8) mean age
86.061.4 y, PD (n=8) mean age 82.062.4 y (t-test, p=0.2).
The PD-related changes in lipid profiles were then used to inform
a targeted assessment of changes in the expression of relevant
genes involved in each of the lipid biosynthetic pathways.
Changes in sphingolipid metabolism related to PD
To confirm the changes in sphingolipid metabolism identified
by LC/MS lipidomics, separate aliquots of brain tissue were
analysed by electrospray ionisation (ESI)/MS. The results for this
analysis were significantly correlated (r
2=0.59, p,0.0001) with
the LC/MS lipidomics data (Fig. 4A, Table S6). Figure 4A
indicates a degree of variation in this correlation that may be due
to differences in the lipid extraction methods and MS analytical
techniques employed (as summarized in Fig. S1). The ESI/MS
analysis did however confirm that levels of sphingolipids (SM and
Cer) were increased in the PD VC (Table S6 and Table S7). There
were no significant correlations between age and either SM or Cer
in the entire cohort (data not shown). The PD-related changes in
SM and Cer were also detected in the smaller age-matched group
comparison (n=8, data not shown). This lack of impact of age was
expected as previous data indicates that changes in these
sphingolipids across the ages of the brain samples used in our
study would be extremely small and thus undetectable [57,58].
In order to understand the underlying mechanisms that may
contribute to regional changes in sphingolipid metabolism in PD,
we assessed the expression of a selection of sphingolipid pathway
genes in the full sample cohort by qRT-PCR. A simplified scheme
depicting the sphingolipid pathway with relevant lipids and genes
we have focused on is shown in Figure 4B. The gene expression
data indicated a significant up-regulation of several genes involved
in Cer and SM synthesis (SPTLC2, FVT1, DEGS1, SGMS1) in
the PD VC (Fig. 5). This is in general agreement with the
lipidomics LC/MS and ESI/MS data and suggests that transcrip-
tional activation contributes to the increased levels of Cer and SM
detected in the PD VC. The increased levels of SL detected in the
PD VC were not associated with changes in UGT8a or Gal3ST1;
two genes that regulate the conversion of Cer to galactosylcer-
amide (GalCer) and SL, respectively (Fig. 5). This may indicate
that increased levels of SL detected in the PD VC are the result of
decreased SL catabolism or that the level of expression of
UGT8a/Gal3ST1 is sufficient to catalyse the conversion of a
Figure 3. Heat map illustrating significant changes in lipid levels associated with Parkinson’s disease as assessed using a lipidomics
approach. Control (n=10) and PD (n=10) tissues were collected from the anterior cingulate cortex (ACC), amygdala (AMY) and visual cortex (VC).
Lipids were extracted and analysed using an LC/MS lipidomics approach. The data indicates the fold change in the levels of sphingolipids,
glycerophospholipids and neutral lipids detected in the PD samples relative to the Con samples. The intensity of the red and green colour represents
the magnitude of increase or decrease, respectively, as indicated by the scale bar. Only statistically significant changes (p,0.05, t-test) are
represented by the red and green colours in the heat map. Note: the nomenclature for phospholipid acyl chain length and saturation is abbreviated
to improve clarity. The data used to generate the heat map is included as Tables S2 to S4.
doi:10.1371/journal.pone.0017299.g003
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and SL.
Changes in glycerophospholipid metabolism related to
PD
We next focused on changes in glycerophospholipid metabolism
that were revealed by the LC/MS lipidomics analysis. Although
one of the glycerophospholipid molecular species (PC16:0/18:2) in
one brain region (AMY) was found to be negatively correlated with
age (Pearson correlation for whole group r
2=20.34, p=0.009, for
smaller age-corrected group r
2=20.58, p=0.001), age did not
contribute to PD-related differences in PC16:0/18:2 (i.e. rather
than increased, the levels of this lipid were either unchanged or
decreased in the PD tissues, Table S3). Previous detailed studies
are consistent with only a very subtle decrease in glyceropho-
spholipid levels with age [59]. The changes detected in PD are
therefore not likely to be influenced by age in our analyses.
To understand the underlying mechanisms that may contribute
to regional changes in glycerophospholipid metabolism in PD, we
assessed the expression of a selection of relevant genes in the full
sample cohort by qRT-PCR (as depicted in Figure 6). Of the genes
investigated, the data indicated that PCYT1A was significantly up-
regulated in the PD VC. This gene is important for the production
of CDP-choline which is required to synthesise PC (Fig. 6).
Interestingly, not all species of PC were increased in the PD VC
and this may be due to conversion of specific molecular species of
PC to PS. Consistent with this, PS levels were significantly
increased in the PD VC and there was a non-significant trend for a
5-fold increase in the expression of the PTDSS1 gene that encodes
for the enzyme required to catalyse this reaction (Fig. 7). Although
DAG (classified here as a neutral lipid but also a crucial
intermediate in glycerophospholipid synthesis, Fig. 6) levels were
increased in the PD VC (Fig. 3), expression of two genes important
for the synthesis of DAG from PA (PPAP2A and PPAP2B) were
not significantly changed; although a trend for up-regulation was
detected in the VC but not in the ACC or AMY (Fig. 7). Overall,
the data point towards subtle modulation of the glyceropho-
spholipid biosynthetic pathway to selectively modify glyceropho-
spholipid profiles in the PD VC. The induction of the PCYT1A
gene in the PD VC suggests that at least part of this change in lipid
profile is transcriptionally regulated.
Changes in neutral lipid and sterol metabolism related to
PD
The lipidomics LC/MS analysis indicated that TAG levels were
decreased in the PD VC but not in the ACC or AMY as compared
to the same brain regions derived from control samples (Fig. 3).
This could also contribute to the increase in DAG detected in the
PD VC (discussed above) as TAG are derived from DAG (Fig. 6).
The lipidomics analysis also revealed an increase in cholesterol
levels in the PD VC (Fig. 3). We re-assessed this by analysing an
independent set of replicate samples by reversed phase HPLC.
This analysis confirmed the lipidomics data (Fig. 8A), although the
magnitude of increase in PD VC cholesterol was different (36% by
LC/MS and 15% by HPLC). The lipid-soluble anti-oxidant a-
tocopherol, which eluted from the HPLC column before
cholesterol, was also quantified. a-Tocopherol levels were not
Figure 4. Comparison of liquid chromatography-mass spec-
trometry (LC/MS; National university of Singapore, NUS) and
electrospray ionisation mass spectrometry (ESI/MS; University
of Wollongong, UOW) techniques for the detection of sphin-
golipid changes in control (Con) and Parkinson’s disease (PD)
tissues. Independent aliquots of Con (n=10) and PD (n=10) tissues
were collected from the anterior cingulate cortex, amygdala and visual
cortex. Lipids were extracted and analysed using LC/MS lipidomics at
NUS (LC/MS NUS) and ESI/MS at UOW (ESI/MS UOW). The fold-change in
lipid levels of the PD samples relative to the controls is provided in the
scatter plot that compares the data from the two laboratories (A). A
simplified schematic diagram of relevant sphingolipids and related
genes assessed in this study is provided (B). The lipids in the boxes with
black borders were analysed in the present study. Serine palmitoyl-
transferase, long chain base subunit 2 (SPTLC2); follicular lymphoma
variant translocation 1 (FVT1); degenerative spermatocyte homolog 1;
lipid desaturase (DEGS1); sphingomyelin synthase 1 (SGMS1); UDP
galactosyltransferase 8A (UGT8A); and galactose-3-O-sulfotransferase 1
(GAL3ST1). Pearson correlation analysis indicates a positive correlation
between the independent analyses (p,0.0001).
doi:10.1371/journal.pone.0017299.g004
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brain regions examined (Fig. 8B). Age was not correlated with either
cholesterol or a-tocopherol levels in any brain region (data not
shown) and was therefore unlikely to confound the PD-related
changes in cholesterol that we detected. The increase in PD VC
cholesterol levels detected could theoretically be due to decreased
formationof CE, however, only one of the ten CE molecular species
analysed was found to be reduced (Fig. 3) and the relative amount of
CE present in the brain is at least two orders of magnitude lower
than cholesterol; so this is unlikely to be a major factor.
In order to understand if cholesterol synthesis or metabolism
may be altered in the PD VC, a further investigation of cholesterol
biosynthetic precursor molecules as well as a range of oxysterol
metabolites, that are indicated by the scheme depicted in Figure 9,
was carried out using GC/MS analysis of the full sample cohort.
There were no significant increases in any of the seven cholesterol
precursor molecules assessed in any of the brain regions (Fig. 10).
Intriguingly, lathosterol and 7-dehydrocholesterol levels were
significantly reduced in the PD ACC compared to the control
ACC (Fig. 10). The significance of this finding is not clear since the
cholesterol levels were not different in the PD ACC versus control
ACC (Figs. 3 and 8). Lathosterol was the only cholesterol
precursor found to be correlated with age. This correlation was
weak and only observed in the ACC (r
2=20.23, p=0.031). Age
did not appear to have a major impact on the magnitude of PD-
related differences in ACC lathosterol levels we detected in the full
Figure 5. Quantitative real-time PCR analysis of selected sphingolipid-related genes in the anterior cingulate cortex (ACC),
amygdala (AMY) and visual cortex (VC) of control (Con) and Parkinson’s disease (PD) tissues. The expression of genes involved in the
sphingolipid biosynthetic pathway (see Fig. 4B) was assessed by qRT-PCR. Data for all genes are expressed relative to the control values (Con = white
bars, assigned a value of 1.0; PD = black bars). The data are presented separately for ACC (A), AMY (B) and VC (C). Serine palmitoyltransferase, long
chain base subunit 2 (SPTLC2); follicular lymphoma variant translocation 1 (FVT1); degenerative spermatocyte homolog 1, lipid desaturase (DEGS);
sphingomyelin synthase 1 (SGMS1); UDP galactosyltransferase 8A (UGT8A); and galactose-3-O-sulfotransferase 1 (GAL3ST1). Data represent mean 6
SEM, *p,0.05 by t-test.
doi:10.1371/journal.pone.0017299.g005
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matched samples (i.e. in the full cohort lathosterol levels were
24.162.4 ng/mg and 16.162.3 in the Con (n=10) and PD
(n=10) groups, respectively (t-test p=0.026); whereas in the age-
matched cohort lathosterol levels were 23.662.8 ng/mg and
16.862.6 in the Con (n=8) and PD (n=8) groups, respectively (t-
test p=0.097).
One possible explanation for the lack of correlation between the
levels of cholesterol and its precursors in the ACC and VC could
be due to different rates of conversion of cholesterol to oxysterols
in the different groups. To assess this, GC/MS was used to
measure several oxysterols that are formed by free-radical
mediated oxidation (7a-OH-Ch, 7b-OH-Ch, 5,6a-epoxy-Ch,
5,6b-epoxy-Ch, 7keto-Ch) or by enzymatic pathways (7a-OH-
Ch, 27-OH-Ch, 24S-OH-Ch) [note: 7a-OH-Ch may be formed
by both enzymatic and oxidative routes [60]].
The GC/MS analysis revealed a significant increase in PD VC
oxysterols derived from both enzymatic and non-enzymatic routes
(Fig. 11). Of the seven oxysterols analysed, 5,6a-epoxy-Ch was the
only compound that was not significantly increased (although
there was a trend for an increase) in the PD VC (Fig. 11). 7Keto-
Ch was the only oxysterol found to be correlated with age. This
correlation was weak and only observed in the VC (r
2=0.20,
p=0.049). Similar to the observations regarding lathosterol above,
age did not have an impact on the magnitude of PD-related
differences in VC 7keto-Ch levels we detected in the full sample
cohort as very similar data were generated using the age-matched
samples (i.e. in the full cohort 7keto-Ch levels were 2.7460.40 ng/
mg and 4.7360.40 in the Con (n=10) and PD (n=10) groups,
respectively (t-test p=0.002); whereas in the age-matched cohort
7keto-Ch levels were 2.8360.49 ng/mg and 4.8660.49 in the
Con (n=8) and PD (n=8) groups, respectively (t-test p=0.011).
Our finding that the levels of several oxysterols are increased in
the PD VC raises two important issues. Firstly, it suggests that the
small increase in total cholesterol levels detected in the PD VC
(Fig. 8) is not due to decreased conversion to oxysterols such as
Figure 6. Simplified scheme of relevant glycerophospholipids and related genes assessed in this study. A simplified schematic diagram
of relevant glycerophospholipids and related genes assessed in this study. The lipids in the boxes with black borders were analysed in the present
study. Phosphatidylcholine (PC); phosphatidic acid (PA); phosphatidylinositol PI; phosphatidylserine PS; phosphatidylethanolamine (PE);
diacylglycerol (DAG); cytidine diphosphate-diacylglycerol (CDP-DAG); cytidinediphosphate-choline (CDP-Choline); cytidinediphosphate-ethanolamine
(CDP-Etn); phosphocholine cytidylytransferase 1a (PCYT1A); phosphatidic acid phosphatase 2a (PPAP2A); phosphatidic acid phosphatase 2B
(PPAP2B); phosphatidylserine synthase I (PtDSS1).
doi:10.1371/journal.pone.0017299.g006
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oxidation products implies the PD VC may be under a state of
oxidative stress. To explore these issues, we conducted further
analysis of gene expression in the full cohort.
We first examined the expression of HMGCR, the rate-limiting
gene controlling cholesterol synthesis, and trends for increases
were detected in all regions of the PD brain examined although
this increase was significant only for the PD VC (Fig. 12). This is in
general agreement with the lipidomics and HPLC data that
indicated a statistically significant elevation of cholesterol only in
the PD VC (Figs. 3 and 8). In addition, CYP24 expression was
significantly increased in the PD VC (which may explain the
increased levels of 24S-OH-Ch detected by GC/MS) whereas
there was only a trend for increased CYP27 expression (Fig. 12).
Interestingly, increases in SOD1, GPX1 and APOD gene
expression were detected in the PD VC (Fig. 12). SOD1, APOD
and specific GPX genes are also up-regulated in the human brain
under oxidative stress conditions and have been shown to be
correlated with increases in markers of brain lipid peroxidation in
the human prefrontal cortex during development and ageing and
in the SN in PD [55,61].
We also used GC/MS to analyse levels of F2-isoprostanes
(sensitive markers of arachidonic acid oxidation) and found no
evidence for an increase in any of the PD samples (A. Jenner, D.
Cheng and B. Garner, unpublished observations). This, along with
the fact that a-tocopherol levels were not depleted in the PD
tissues (Fig. 8), implies that the increase in oxidative stress in the
PD VC is not a ‘‘generalised’’ condition but may be rather specific
(e.g. perhaps limited to cholesterol). As it has been shown
previously that 27-OH-Ch up-regulates neuronal a-syn mRNA
expression [62], we also assessed SYNA gene expression and the
results indicate there were no differences related to either 27-OH-
Ch levels or to PD status (Fig. 12). The failure of the increased
levels of 27-OH-Ch present in the PD VC to induce a-syn
transcription may be due to a complex interplay with 24S-OH-Ch
as another study has suggested that 27-OH-Ch-mediated up-
regulation of SYNA can be blocked in the presence of equimolar
24S-OH-Ch [63].
Discussion
The data presented herein represent the first lipidomics analysis
of the human PD brain. Although previous work focused on lipid
changes detectable in the SN using histochemical techniques [5],
we have chosen not to focus our present study on the SN for two
Figure 7. Quantitative real-time PCR analysis of selected
glycerophospholipid-related genes in the anterior cingulate
cortex (ACC), amygdala (AMY) and visual cortex (VC) of control
(Con) and Parkinson’s disease (PD) tissues. The expression of
genes involved in the glycerophospholipid biosynthetic pathway (see
Fig. 6) was assessed by qRT-PCR. Data for all genes are expressed
relative to the control values (Con = white bars, assigned a value of 1.0;
PD = black bars). The data are presented separately for ACC (A), AMY
(B) and VC (C). Phosphocholine cytidylytransferase 1a (PCYT1A);
Phosphatidic acid phosphatase 2a (PPAP2A); phosphatidic acid
phosphatase 2B (PPAP2B); Phosphatidylserine synthase I (PtDSS1). Data
represent mean 6 SEM, *p,0.05 by t-test.
doi:10.1371/journal.pone.0017299.g007
Figure 8. High performance liquid chromatography (HPLC)
analysis of cholesterol and a-tocopherol in the anterior
cingulate cortex (ACC), amygdala (AMY) and visual cortex
(VC) of control (Con) and Parkinson’s disease (PD) tissues.
Cholesterol (A) and a-tocopherol (B) levels were analysed in the ACC,
AMY and VC of Con (white bars) and PD (black bars) tissues by reversed
phase HPLC. Data represent mean 6 SEM, *p,0.05 by t-test.
doi:10.1371/journal.pone.0017299.g008
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PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e17299Figure 9. Simplified schematic diagram of cholesterol synthesis, cholesterol metabolites and selected relevant genes analysed in
this study. The lipids in the boxes with black borders were analysed in the present study. The broken lines indicated additional intermediates are
present in the pathway but they are not not shown in the scheme. The oxysterols that are followed by a dot ‘‘N’’ are formed by non-enzymatic
oxidative reactions. The symbol ‘‘(N)’’ indicates the oxysterol is formed via both enzymatic and non-enzymatic routes. 24-hydroxycholesterol (24-OH
Ch); 27-hydroxycholesterol (27-OH Ch); 7keto-cholesterol (7keto Ch); cholesterol-5a,6a-epoxide (5,6a-Epoxy Ch); cholesterol-5b,6b-epoxide (5,6b-
Epoxy Ch); 7a-hydroxycholesterol (7a-OH Ch); 7b-hydroxycholesterol (7b-OH Ch); 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR); cytochrome
P450, family 24, subfamily A, polypeptide 1 (CYP24); cytochrome P450, family 27, subfamily A, polypeptide 1 (CYP27).
doi:10.1371/journal.pone.0017299.g009
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in the SN in association with PD would obscure interpretation of
any changes in lipid metabolism that may be revealed by a
lipidomics analysis [3,7,64], and secondly, the loss of neuromela-
nin from the SN in PD will similarly confound the lipid analysis as
this pigment is enriched in lipids including cholesterol and, in
particular, dolichol [54].
The most important findings arising from our current work relate
to changes in lipid metabolism in the PD VC. It should be
emphasised that there are no substantive pathological changes
observed in this region of the brain in PD; although previous studies
have indicated changes in metabolic activity by PET and fMRI
techniques [20–23]. Our data indicate an activation of the
sphingolipid biosynthetic pathway in the PD VC that appears to be
regulated at the transcriptional level. Increases in specific ceramide
species and other sphingolipids may alter intracellular signalling and
contribute to neuronal dysfunction in PD [65]. Similarly, alterations
in DAG and glycerophospholipid metabolism may also modulate
neuronal function in the PD VC [66]. We speculate that such
significant changes in lipid metabolism might result in neuronal
dysfunction of the primary VC in PD and that these changes may
impact on visual perception and possibly contribute to VH.
Oxidative stressresultingin lipid peroxidationhas been suggested
to cause neuronal death in the PD SN [67,68]. Cholesterol is highly
enriched in the brain and previous studies have shown that specific
oxysterols (e.g. 7b-OH-Ch and 24S-OH-Ch) may be neurotoxic at
reasonably high mM concentrations [69,70]. At sub-lethal concen-
trations, oxysterols including 27-OH-Ch and 24S-OH-Ch can also
regulate the transcription ofa-synandmany othergenesinvolved in
neuroinflammation and neurodegeneration via the liver-X-receptor
(LXR) pathway [62,63,71–73]. Very recently, oxysterol-mediated
LXR activation of human embryonic stem cells (hESC) has been
shown to increase neurogenesis and this led to the suggestion that
oxysterols may be used to improve hESC replacement strategies for
Figure 10. Gas chromatography mass spectrometry (GC/MS) analysis of cholesterol precursors in the anterior cingulate cortex
(ACC), amygdala (AMY) and visual cortex (VC) of control (Con) and Parkinson’s disease (PD) tissues. Control (n=10) and PD (n=10)
tissues were collected from the ACC (A), AMY (B) and VC (C). Lipids were extracted and cholesterol precursors analysed using GC/MS. The data
indicates the fold change in the levels of cholesterol precursors detected in the PD (black bars) samples relative to the Con (white bars) samples.
Absolute values for the cholesterol precursors in the different brain regions are provided as Table S8. Squalene (Squa); lanosterol (Lano), 14-dimethyl
lanosterol (14-DL), zymosterol (Zymo), desmosterol (Desmo), lathosterol (Latho), 7-dehyrocholesterol (7-DC). Data represent mean 6 SEM.
doi:10.1371/journal.pone.0017299.g010
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considered deleterious, it is possible that increases in certain
oxysterols we have observed in the VC may perform a function that
is protective in the PD context.
Another consideration is the source of oxysterol increase we have
detected in the PD VC. Our assumption is that the oxysterols are
mostly locally produced, and this would fit with the changes in
CYP24 expression that our data indicate are correlated with
increased 24S-OH-Ch; however, it is quite likely that the increase
in 27-OH-Ch we detected could also be due to plasma derived
oxysterol. Relevant to this point, recent studies have shown that 27-
OH-ChlevelsaresignificantlyelevatedinPDplasma[75,76].Similar
ideas have been put forwardregarding the source of elevated 27-OH-
Ch levels in Alzheimer’s disease brain where, intriguingly, levels of
this oxysterol are also elevated in the occipital cortex [77,78].
Our current study has also revealed for the first time that there
is an up-regulation of antioxidant response genes in the PD VC.
Oxidative stress has been well established as a causative factor in
the pathways that result in neuron loss within the SN in PD [67];
however, due to the lack of pathology in the VC, the up-regulation
of genes such as SOD1, GPX1 and APOD that we detected was
rather unexpected. It is possible that hypoperfusion of the PD VC
that is associated with hypometabolism of glucose could result in
less efficient production of reducing equivalents through the Krebs
cycle and thereby place the origin of the oxidative stress response
at the level of metabolic changes in the mitochondria (of neurons
and/or astroglial cells) [79,80]. Interestingly, previous work has
shown that glial apoD and GPX1 levels are increased in the SN in
PD cases [61,81,82]. From these studies it was concluded that glia
may afford neuroprotection in the SN and it remains possible that
a similar process occurs in the VC in PD.
It is currently not known if the changes we have detected in lipid
homeostasis and oxidative stress in the VC are specific for PD. As
noted above, oxysterol metabolism is altered in the occipital cortex
Figure 11. Gas chromatography mass spectrometry (GC/MS) analysis of oxysterols in the anterior cingulate cortex (ACC), amygdala
(AMY) and visual cortex (VC) of control (Con) and Parkinson’s disease (PD) tissues. Control (n=10) and PD (n=10) tissues were collected
from the ACC (A), AMY (B) and VC (C). Lipids were extracted and oxysterols analysed using GC/MS. The data indicates the fold change in the levels of
oxysterols detected in the PD (black bars) samples relative to the Con (white bars) samples. 7a-hydroxycholesterol (7aOHC); 7b-hydroxycholesterol
(7bOHC); cholesterol-5a,6a-epoxide (5,6aEC); cholesterol-5b,6b-epoxide (5,6bEC); 7keto-cholesterol (7KC); 27-hydroxycholesterol (27OHC); 24-
hydroxycholesterol (24OHC). Data represent mean 6 SEM, *p,0.05, **p,0.001 by t-test.
doi:10.1371/journal.pone.0017299.g011
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injury induced by trauma or stroke alters lipid peroxidation status
[83–85]. Furthermore, data from animal studies indicate that
bioactive oxysterols, such as 24S-OH-Ch, increase in response to
traumatic brain injury and this can modulate the transcription of
specific genes that regulate lipid homeostasis [86]. Interestingly, it
has been reported that visual hallucinations are present in ,30%
of Alzheimer’s disease patients [87]. Similarly, VH have been
reported in association with both stroke and traumatic brain injury
[88,89]. Based on the fact that alterations in cerebral lipid
homeostasis and oxidative stress status appear to coexist with VH
in other neurological conditions, we cannot exclude the possibility
that the changes in lipid homeostasis and oxidative stress we have
detected in the PD VC may be a generalised phenomenon that is
not specific to PD VH. Further studies that compare cerebral lipid
homeostasis in large cohorts of PD patients both with and without
VH would provide further evidence for a specific association.
In conclusion, our studies reveal significant alterations in the
sphingolipid and glycerophospholipid pathways in the primary VC
inidiopathicPD.Wealsoshow that cholesterolmetabolism through
the oxysterol pathway is up-regulated in the PD VC. These changes
are associated with selective changes in the expression of genes
responsible for the control of lipid biosynthesis and with increased
expression of antioxidant genes. Although causation can not be
established from these studies, the data do suggest that normaliza-
tion of the dysregulated lipid metabolism/oxidative stress status in
the VC may represent a novel route for treatment of the VH that
are experienced by a majority of PD patients.
Figure 12. Quantitative real-time PCR analysis of selected sterol-related and oxidative stress-related genes in the anterior cingulate
cortex (ACC), amygdala (AMY) and visual cortex (VC) of control (Con) and Parkinson’s disease (PD) tissues. The expression of genes
involved in cholesterol metabolism and oxidative stress was assessed by qRT-PCR. Data for all genes are expressed relative to the control values (Con
= white bars, assigned a value of 1.0; PD = black bars). The data are presented separately for ACC (A), AMY (B) and VC (C). 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMG); cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24); cytochrome P450, family 27, subfamily A, polypeptide
1 (CYP27); superoxide dismutase 1 (SOD1); glutathione peroxidase 1 (GPX1); glutathione peroxidase 3 (GPX3); Apolipoprotein-D (APOD); a-synuclein
(SNCA). Data represent mean 6 SEM, *p,0.05 by t-test.
doi:10.1371/journal.pone.0017299.g012
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Figure S1 Workflow of lipidomic screening strategy.
The strategy for human brain tissue sample collection, distribution
and analysis of the major lipid classes is illustrated.
(TIF)
Figure S2 Analysis of a-synuclein is SDS fraction
Parkinson’s disease amygdala. Tissues were homogenised
into three fractions that contained tris-buffered saline, TBS
containing Triton X100 or sodium dodecyl sulphate (SDS) and
a-synuclein (a-Syn) expression was analysed by Western blotting.
The detection of high molecular weight species of a-syn are
indicated, the arrow indicates a 31 kDa a-Syn band that is present
in some of the human brain SDS fractions. The data are derived
from Parkinson’s disease amygdala (PD AMY) samples.
(TIF)
Table S1 qRT-PCR primer details. Primers were designed
using Primer3 software (available at http://www.ncbi.nlm.nih.
gov/) and based on the National Center for Biotechnology
Information (NCBI) reference sequences. The specificity of the
primers was confirmed by demonstration of a single PCR product
of the correct size as judged by agarose gel electrophoresis.
(DOC)
Table S2 Changes in lipid levels associated with
Parkinson’s disease (PD) anterior cingulate cortex as
assessed using a lipidomics approach. Control (n=10) and
PD Patient (n=10) tissues were collected from the anterior
cingulate cortex (ACC). Lipids were extracted and analysed using
an LC/MS lipidomics approach. The data indicates mol% values
for all lipid species listed in the Table. The fold-change values in
the levels of sphingolipids, glycerophospholipids and neutral lipids
detected in the PD patient samples relative to the Con samples are
provided (‘‘Ratio’’) along with the t-test p-values. These data were
used to generate the heat map provided in Figure 3.
(XLS)
Table S3 Changes in lipid levels associated with
Parkinson’s disease (PD) amygdala as assessed using a
lipidomics approach. Control (n=10) and PD Patient (n=10)
tissues were collected from the amygdala (AMY). Lipids were
extracted and analysed using an LC/MS lipidomics approach.
The data indicates mol% values for all lipid species listed in the
Table. The fold-change values in the levels of sphingolipids,
glycerophospholipids and neutral lipids detected in the PD patient
samples relative to the Con samples are provided (‘‘Ratio’’) along
with the t-test p-values. These data were used to generate the heat
map provided in Figure 3.
(XLS)
Table S4 Changes in lipid levels associated with
Parkinson’s disease (PD) primary visual cortex as
assessed using a lipidomics approach. Control (n=10)
and PD Patient (n=10) tissues were collected from the primary
visual cortex (VC). Lipids were extracted and analysed using an
LC/MS lipidomics approach. The data indicates mol% values for
all lipid species listed in the Table. The fold-change values in the
levels of sphingolipids, glycerophospholipids and neutral lipids
detected in the PD patient samples relative to the Con samples are
provided (‘‘Ratio’’) along with the t-test p-values. These data were
used to generate the heat map provided in Figure 3.
(XLS)
Table S5 False discovery rate (FDR) analysis for the
lipidomics data sets. False discovery rate (FDR) q-values were
calculated from the t-test p-values for the lipidomics datasets
provided in Tables S2 to S4. Data are sorted based on p-value
ascending order. VC, visual cortex; AMY, amygdala; ACC,
anterior cingulate cortex.
(XLS)
Table S6 Comparison of electrospray ionisation mass
spectrometry and liquid chromatography mass spec-
trometry data. All values represent the fold-change in PD lipids
relative to the control cases. UOW ESI/MS, University of
Wollongong electrospray ionisation mass spectrometry; National
University of Singapore, liquid chromatography mass spectrom-
etry.
(DOC)
Table S7 Brain sphingolipid quantification by electro-
spray ionisation mass spectrometry. Semi-quantitative
analysis of the major sphingolipid species present in Control and
PD brain samples was assessed by ESI/MS. All values are nmol/g
tissue (wet weight). Note that changes in pulverized tissue sample
moisture content during storage of samples at 280uC may
influence the absolute quantities of lipids given in the Table.
(DOC)
Table S8 Cholesterol precursor quantification by gas
chromatography mass spectrometry. Semi-quantitative
analysis of the major cholesterol precursor species present in
brain samples was assessed by GC/MS. All values are ng/mg
tissue (wet weight). Note that changes in pulverized tissue sample
moisture content during storage of samples at 280uC may
influence the absolute quantities of lipids given in the Table.
(XLS)
Methods S1 Detailed methods.
(DOC)
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